[go: up one dir, main page]

ES2159564T3 - Preparados farmaceuticos para principios activos dificilmente solubles. - Google Patents

Preparados farmaceuticos para principios activos dificilmente solubles.

Info

Publication number
ES2159564T3
ES2159564T3 ES94922269T ES94922269T ES2159564T3 ES 2159564 T3 ES2159564 T3 ES 2159564T3 ES 94922269 T ES94922269 T ES 94922269T ES 94922269 T ES94922269 T ES 94922269T ES 2159564 T3 ES2159564 T3 ES 2159564T3
Authority
ES
Spain
Prior art keywords
diffically
pharmaceutical preparations
soluble active
active principles
acid esters
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES94922269T
Other languages
English (en)
Inventor
Ulrich Posanski
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=6492300&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2159564(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis AG filed Critical Novartis AG
Application granted granted Critical
Publication of ES2159564T3 publication Critical patent/ES2159564T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Transplantation (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

LA PRESENTE INVENCION SE REFIERE A PREPARACIONES FARMACEUTICAS PARA SUSTANCIAS ACTIVAS DIFICILMENTE SOLUBLES, ASI COMO PROCESO PARA LA ELABORACION DE ESTOS PREPARADOS. COMO MEDIOS DE SOLUBILIZACION SE UTILIZAN ESTERES DE ACIDO GRASO POLIGLICERINA O ESTERES DE ACIDO GRASO SORBITANO EN COMBINACION CON SUSTANCIAS AUXILIARES LIPOFILAS Y SURFACTANTES NO IONICOS.
ES94922269T 1993-07-08 1994-07-08 Preparados farmaceuticos para principios activos dificilmente solubles. Expired - Lifetime ES2159564T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE4322826A DE4322826A1 (de) 1993-07-08 1993-07-08 Pharmazeutisches Präparat

Publications (1)

Publication Number Publication Date
ES2159564T3 true ES2159564T3 (es) 2001-10-16

Family

ID=6492300

Family Applications (3)

Application Number Title Priority Date Filing Date
ES94922269T Expired - Lifetime ES2159564T3 (es) 1993-07-08 1994-07-08 Preparados farmaceuticos para principios activos dificilmente solubles.
ES94923715T Expired - Lifetime ES2124420T3 (es) 1993-07-08 1994-07-08 Preparados farmaceuticos para productos activos dificilmente solubles.
ES00122248T Expired - Lifetime ES2218046T3 (es) 1993-07-08 1994-07-08 Preparaciones farmaceuticas para principios activos dificilmente solubles.

Family Applications After (2)

Application Number Title Priority Date Filing Date
ES94923715T Expired - Lifetime ES2124420T3 (es) 1993-07-08 1994-07-08 Preparados farmaceuticos para productos activos dificilmente solubles.
ES00122248T Expired - Lifetime ES2218046T3 (es) 1993-07-08 1994-07-08 Preparaciones farmaceuticas para principios activos dificilmente solubles.

Country Status (24)

Country Link
EP (3) EP0710103B1 (es)
JP (4) JPH08512301A (es)
KR (2) KR100386533B1 (es)
CN (2) CN1121853C (es)
AT (3) ATE172876T1 (es)
AU (2) AU689486B2 (es)
BR (1) BR9407002A (es)
CA (2) CA2166204C (es)
CY (2) CY2308B1 (es)
CZ (1) CZ291401B6 (es)
DE (6) DE4322826A1 (es)
DK (3) DK1092429T3 (es)
ES (3) ES2159564T3 (es)
FI (2) FI116197B (es)
GR (1) GR3036571T3 (es)
HU (2) HU228127B1 (es)
NO (2) NO306763B1 (es)
NZ (2) NZ269552A (es)
PL (1) PL179717B1 (es)
PT (2) PT710103E (es)
RU (1) RU2140291C1 (es)
SI (1) SI1092429T1 (es)
SK (1) SK280615B6 (es)
WO (2) WO1995001786A1 (es)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8920820B2 (en) 2001-12-12 2014-12-30 Boehringer Ingelheim Vetmedica Gmbh Highly concentrated stable meloxicam solutions for needleless injection
US8992980B2 (en) 2002-10-25 2015-03-31 Boehringer Ingelheim Vetmedica Gmbh Water-soluble meloxicam granules
US9101529B2 (en) 2009-10-12 2015-08-11 Boehringer Ingelheim Vetmedica Gmbh Containers for compositions comprising meloxicam
US9149480B2 (en) 2010-03-03 2015-10-06 Boehringer Ingeleheim Vetmedica GmbH Use of meloxicam for the long-term treatment of musculoskeletal disorders in cats
US9795568B2 (en) 2010-05-05 2017-10-24 Boehringer Ingelheim Vetmedica Gmbh Low concentration meloxicam tablets
US9993557B2 (en) 2000-06-20 2018-06-12 Boehringer Ingelheim Vetmedica Gmbh Highly concentrated stable meloxicam solutions
US10548901B2 (en) 2004-02-23 2020-02-04 Boehringer Ingelheim Vetmedica Gmbh Meloxicam for the treatment of respiratory diseases in pigs

Families Citing this family (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH686761A5 (de) 1993-05-27 1996-06-28 Sandoz Ag Galenische Formulierungen.
DE4322826A1 (de) * 1993-07-08 1995-01-12 Galenik Labor Freiburg Gmbh Pharmazeutisches Präparat
GB9409778D0 (en) 1994-05-16 1994-07-06 Dumex Ltd As Compositions
US6413536B1 (en) * 1995-06-07 2002-07-02 Southern Biosystems, Inc. High viscosity liquid controlled delivery system and medical or surgical device
US6696413B2 (en) * 1995-06-16 2004-02-24 Hexal Ag Pharmaceutical preparation with cyclosporin A
BE1009856A5 (fr) 1995-07-14 1997-10-07 Sandoz Sa Composition pharmaceutique sous la forme d'une dispersion solide comprenant un macrolide et un vehicule.
GB9514878D0 (en) * 1995-07-20 1995-09-20 Danbiosyst Uk Vitamin E as a solubilizer for drugs contained in lipid vehicles
GB2317562B (en) * 1995-07-20 1999-08-18 Danbiosyst Uk Lipid vehicle drug delivery composition containing vitamin E
US5597582A (en) * 1995-09-12 1997-01-28 Sanofi Oral gel capsule formulation of 1,2,4-benzotriazine oxides
DE19549852B4 (de) * 1995-11-29 2009-06-04 Novartis Ag Cyclosporin enthaltende Präparate
CZ288631B6 (cs) * 1996-01-18 2001-08-15 Galena, A. S. Léčivé přípravky s obsahem cyklosporinu
CZ288739B6 (cs) * 1996-08-01 2001-08-15 Galena, A. S. Cyklosporin obsahující léčivé přípravky
US6458373B1 (en) 1997-01-07 2002-10-01 Sonus Pharmaceuticals, Inc. Emulsion vehicle for poorly soluble drugs
GB9705813D0 (en) * 1997-03-20 1997-05-07 Smithkline Beecham Plc Novel compositions
KR20010006070A (ko) * 1997-04-11 2001-01-15 후지야마 아키라 의약조성물
US6365180B1 (en) * 1998-01-20 2002-04-02 Glenn A. Meyer Oral liquid compositions
ID25908A (id) * 1998-03-06 2000-11-09 Novartis Ag Prakonsentrat-prakonsentrat emulsi yang mengandung siklosporin atau makrolida
US7030155B2 (en) 1998-06-05 2006-04-18 Sonus Pharmaceuticals, Inc. Emulsion vehicle for poorly soluble drugs
GB2344520A (en) * 1998-12-08 2000-06-14 Phares Pharm Res Nv Pharmaceutical carriers comprising lipids and polymers
US7026290B1 (en) 1998-12-30 2006-04-11 Dexcel Ltd. Dispersible concentrate for the delivery of cyclosprin
EP1221947B1 (en) * 1999-10-01 2004-12-08 Natco Pharma Limited Soft gel capsule resistant to gastric juices
US7732404B2 (en) 1999-12-30 2010-06-08 Dexcel Ltd Pro-nanodispersion for the delivery of cyclosporin
CA2426925A1 (en) * 2000-11-24 2003-04-25 Yamanouchi Pharmaceutical Co., Ltd. Water-soluble liquid internal medicine
AU2002231703B2 (en) 2001-12-14 2007-03-29 Jagotec Ag Pharmaceutical formulation comprising cyclosporin and use thereof
RU2217170C2 (ru) * 2002-02-08 2003-11-27 Мельников Глеб Евгеньевич Дезинфицирующее средство
RU2217169C2 (ru) * 2002-02-08 2003-11-27 Мельников Глеб Евгеньевич Дезинфицирующее средство
KR100533458B1 (ko) * 2002-07-20 2005-12-07 대화제약 주식회사 파클리탁셀의 가용화용 조성물 및 그의 제조 방법
GB2391473B (en) * 2002-08-02 2004-07-07 Satishchandra Punambhai Patel Pharmaceutical compositions
FR2850275B1 (fr) * 2003-01-24 2005-04-08 Scherer Technologies Inc R P Capsules molles a macher contenant une substance active a gout masque
US7517519B2 (en) 2003-02-06 2009-04-14 Cipla Limited Topical immunotherapy and compositions for use therein
WO2004073692A1 (ja) * 2003-02-18 2004-09-02 Yamashita, Shinji 難水溶性薬物のハードカプセル剤
DK2279729T3 (da) * 2003-07-17 2016-11-28 Banner Life Sciences Llc Præparater med kontrolleret frigivelse
TW200616681A (en) * 2004-10-05 2006-06-01 Recordati Ireland Ltd Lercanidipine capsules
GB0425255D0 (en) * 2004-11-16 2004-12-15 Novartis Ag Pharmaceutical composition
US20070027105A1 (en) 2005-07-26 2007-02-01 Alza Corporation Peroxide removal from drug delivery vehicle
BRPI0614417A2 (pt) * 2005-07-28 2011-03-29 Reliant Pharmaceuticals Inc composições farmacêuticas compreendendo bloqueadores de canais de cálcio de dihidropiridina e ácidos graxos de Èmega-3 e métodos de tratamento utilizando as mesmas
GB0526419D0 (en) * 2005-12-23 2006-02-08 Cyclacel Ltd Formulation
EP2484347A1 (en) 2006-11-03 2012-08-08 Durect Corporation Transdermal delivery systems comprising bupivacaine
EP1952807A1 (en) * 2007-01-24 2008-08-06 LEK Pharmaceuticals D.D. Sirolimus formulation
ITMI20070720A1 (it) * 2007-04-06 2008-10-07 Monteresearch Srl Composizioni orali contenenti tacrolimus in forma amorfa
US11304960B2 (en) 2009-01-08 2022-04-19 Chandrashekar Giliyar Steroidal compositions
KR20130128018A (ko) * 2009-04-10 2013-11-25 하이얀 치 새로운 노화 방지 물질 및 그 확인 방법
US9034858B2 (en) 2010-11-30 2015-05-19 Lipocine Inc. High-strength testosterone undecanoate compositions
US9358241B2 (en) 2010-11-30 2016-06-07 Lipocine Inc. High-strength testosterone undecanoate compositions
US20180153904A1 (en) 2010-11-30 2018-06-07 Lipocine Inc. High-strength testosterone undecanoate compositions
US20120148675A1 (en) 2010-12-10 2012-06-14 Basawaraj Chickmath Testosterone undecanoate compositions
JP5970224B2 (ja) 2011-07-11 2016-08-17 株式会社日本自動車部品総合研究所 内燃機関用のスパークプラグ
KR20140071913A (ko) * 2012-12-04 2014-06-12 삼성정밀화학 주식회사 식품 조성물 및 이를 포함하는 연질 캡슐
SG11201508358RA (en) * 2013-04-09 2015-11-27 Boston Biomedical Inc 2-acetylnaphtho[2,3-b]furan -4,9-dione for use on treating cancer
US20170246187A1 (en) 2014-08-28 2017-08-31 Lipocine Inc. (17-ß)-3-OXOANDROST-4-EN-17-YL TRIDECANOATE COMPOSITIONS AND METHODS OF THEIR PREPARATION AND USE
WO2016033556A1 (en) 2014-08-28 2016-03-03 Lipocine Inc. BIOAVAILABLE SOLID STATE (17-β)-HYDROXY-4-ANDROSTEN-3-ONE ESTERS
PT3215127T (pt) * 2014-11-07 2021-02-10 Sublimity Therapeutics Ltd Composições que compreendem ciclosporina
WO2016078481A1 (zh) 2014-11-21 2016-05-26 杭州领业医药科技有限公司 一种含他克莫司的药物组合物及其制备方法
US20160361322A1 (en) 2015-06-15 2016-12-15 Lipocine Inc. Composition and method for oral delivery of androgen prodrugs
WO2017184875A1 (en) 2016-04-20 2017-10-26 Veroscience Llc Composition and method for treating metabolic disorders
US11559530B2 (en) 2016-11-28 2023-01-24 Lipocine Inc. Oral testosterone undecanoate therapy
PL3697418T3 (pl) * 2017-10-18 2025-02-03 Veroscience Llc Polepszone preparaty bromokryptyny
WO2019175253A1 (en) * 2018-03-14 2019-09-19 KaNDy Therapeutics Limited Novel pharmaceutical formulation comprising dual nk-1/nk-3 receptor antagonists
CN108853044B (zh) * 2018-07-06 2020-11-06 郑州明泽医药科技有限公司 一种硝苯地平缓释片及其制备方法
CA3107214A1 (en) 2018-07-20 2020-01-23 Lipocine Inc. Liver disease
WO2021061818A1 (en) 2019-09-23 2021-04-01 Veroscience Llc Method for inducing tumor regression
CA3167217A1 (en) 2020-01-13 2021-07-22 Durect Corporation Sustained release drug delivery systems with reduced impurities and related methods
KR102524312B1 (ko) * 2020-12-15 2023-04-21 윤관식 엑디스테로이드 함유 수용성 유화 조성물
KR102712501B1 (ko) * 2021-02-26 2024-10-02 윤관식 알칼로이드 함유 수용성 유화 조성물
WO2022131656A1 (ko) * 2020-12-15 2022-06-23 윤관식 알칼로이드 함유 수용성 유화 조성물
KR102583074B1 (ko) * 2021-01-25 2023-09-25 윤관식 천연 폴리페놀 화합물 함유 수용성 유화 조성물
CN116940358A (zh) 2021-01-12 2023-10-24 度勒科特公司 持续释放药物递送系统和有关的方法
CN113041236B (zh) * 2021-03-23 2023-03-10 广州新济药业科技有限公司 氟比洛芬巴布剂及其制备方法
KR20240173178A (ko) * 2023-06-02 2024-12-10 주식회사 지엔티파마 안정성 및 용출률이 개선된 크리스데살라진 함유 약학 조성물

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1132518A (en) * 1965-02-18 1968-11-06 Richardson Merrell Inc Medicinal composition
IT1090703B (it) * 1976-12-03 1985-06-26 Scherer Ltd R P Perfezionamento nelle composizioni utili quali veicolo per farmaci
GB8903804D0 (en) * 1989-02-20 1989-04-05 Sandoz Ltd Improvements in or relating to organic compounds
GB8630273D0 (en) * 1986-12-18 1987-01-28 Til Medical Ltd Pharmaceutical delivery systems
EP0327280B1 (en) * 1988-01-29 1992-03-18 Sankyo Company Limited Cyclosporin compositions
GB2222770B (en) * 1988-09-16 1992-07-29 Sandoz Ltd Pharmaceutical compositions containing cyclosporins
HU212924B (en) * 1989-05-25 1996-12-30 Chiron Corp Adjuvant formulation comprising a submicron oil droplet emulsion
CA2038744C (en) * 1990-03-23 2002-01-08 Yoshitomi Pharmaceutical Industries Ltd. Pharmaceutical composition containing slightly water-soluble drug
GB9113872D0 (en) * 1991-06-27 1991-08-14 Sandoz Ag Improvements in or relating to organic compounds
JPH0525037A (ja) * 1991-07-01 1993-02-02 Upjohn Co:The 経口投与酵素感受性腸溶製剤
RU2053764C1 (ru) * 1991-07-19 1996-02-10 Эгиш Дьедьсердьяр Мягкая желатиновая капсула и способ ее получения
DE4322826A1 (de) * 1993-07-08 1995-01-12 Galenik Labor Freiburg Gmbh Pharmazeutisches Präparat

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9993557B2 (en) 2000-06-20 2018-06-12 Boehringer Ingelheim Vetmedica Gmbh Highly concentrated stable meloxicam solutions
US8920820B2 (en) 2001-12-12 2014-12-30 Boehringer Ingelheim Vetmedica Gmbh Highly concentrated stable meloxicam solutions for needleless injection
US10098891B2 (en) 2001-12-12 2018-10-16 Boehringer Ingelheim Vetmedica Gmbh Highly concentrated stable meloxicam solutions for needleless injection
US8992980B2 (en) 2002-10-25 2015-03-31 Boehringer Ingelheim Vetmedica Gmbh Water-soluble meloxicam granules
US9066955B2 (en) 2002-10-25 2015-06-30 Boehringer Ingelheim Vetmedica Gmbh Water-soluble meloxicam granules
US10548901B2 (en) 2004-02-23 2020-02-04 Boehringer Ingelheim Vetmedica Gmbh Meloxicam for the treatment of respiratory diseases in pigs
US9101529B2 (en) 2009-10-12 2015-08-11 Boehringer Ingelheim Vetmedica Gmbh Containers for compositions comprising meloxicam
US9186296B2 (en) 2009-10-12 2015-11-17 Boehringer Ingelheim Vetmedica Gmbh Containers for compositions comprising meloxicam
US9149480B2 (en) 2010-03-03 2015-10-06 Boehringer Ingeleheim Vetmedica GmbH Use of meloxicam for the long-term treatment of musculoskeletal disorders in cats
US9795568B2 (en) 2010-05-05 2017-10-24 Boehringer Ingelheim Vetmedica Gmbh Low concentration meloxicam tablets
US9943486B2 (en) 2010-05-05 2018-04-17 Boehringer Ingelheim Vetmedica Gmbh Low concentration meloxicam tablets

Also Published As

Publication number Publication date
FI960042A0 (fi) 1996-01-04
CN1128495A (zh) 1996-08-07
WO1995001786A1 (de) 1995-01-19
DE4494851D2 (de) 1996-12-19
FI960042L (fi) 1996-01-04
NO306929B1 (no) 2000-01-17
RU2140291C1 (ru) 1999-10-27
AU689486B2 (en) 1998-04-02
AU7345794A (en) 1995-02-06
KR100359044B1 (ko) 2003-02-05
HU9503965D0 (en) 1996-03-28
FI116714B (fi) 2006-02-15
EP0710104A1 (de) 1996-05-08
BR9407002A (pt) 1996-09-03
PT1092429E (pt) 2004-08-31
SI1092429T1 (en) 2004-08-31
JPH08512303A (ja) 1996-12-24
NO960069L (no) 1996-01-05
PL312255A1 (en) 1996-04-01
NZ269808A (en) 1996-07-26
JPH08512301A (ja) 1996-12-24
DK1092429T3 (da) 2004-07-19
WO1995001785A1 (de) 1995-01-19
FI960032A0 (fi) 1996-01-03
DE59410365D1 (de) 2004-04-22
ES2218046T3 (es) 2004-11-16
EP1092429A1 (de) 2001-04-18
NZ269552A (en) 1996-07-26
PL179717B1 (pl) 2000-10-31
JP2009138008A (ja) 2009-06-25
HUT73661A (en) 1996-09-30
DK0710103T3 (da) 2001-09-24
PT710103E (pt) 2001-11-30
CN1313154C (zh) 2007-05-02
EP0710103A1 (de) 1996-05-08
SK1996A3 (en) 1997-04-09
ATE261720T1 (de) 2004-04-15
SK280615B6 (sk) 2000-05-16
CY2308B1 (en) 2003-11-14
HU228127B1 (en) 2012-12-28
AU7385094A (en) 1995-02-06
JP2011153150A (ja) 2011-08-11
EP0710103B1 (de) 2001-06-13
DK0710104T3 (da) 1999-07-19
HU9503868D0 (en) 1996-02-28
CA2166204A1 (en) 1995-01-19
KR100386533B1 (ko) 2003-08-21
CA2166204C (en) 2009-04-14
NO960062L (no) 1996-01-05
CZ4596A3 (en) 1996-04-17
CA2164100A1 (en) 1995-01-19
DE59407239D1 (de) 1998-12-10
CZ291401B6 (cs) 2003-03-12
GR3036571T3 (en) 2001-12-31
ATE172876T1 (de) 1998-11-15
FI960032L (fi) 1996-02-09
CN1121853C (zh) 2003-09-24
DE4494850D2 (de) 1996-08-22
CN1496743A (zh) 2004-05-19
NO306763B1 (no) 1999-12-20
HUT73427A (en) 1996-07-29
CY2604B2 (en) 2010-04-28
NO960069D0 (no) 1996-01-05
NO960062D0 (no) 1996-01-05
DE4322826A1 (de) 1995-01-12
FI116197B (fi) 2005-10-14
DE59409787D1 (de) 2001-07-19
HU223073B1 (hu) 2004-03-01
ES2124420T3 (es) 1999-02-01
ATE201985T1 (de) 2001-06-15
EP0710104B1 (de) 1998-11-04
EP1092429B1 (de) 2004-03-17

Similar Documents

Publication Publication Date Title
ES2159564T3 (es) Preparados farmaceuticos para principios activos dificilmente solubles.
ES2038643T3 (es) Procedimiento para la obtencion de una composicion farmaceutica topica.
FI953442A0 (fi) Gonadotropiinia sisältäviä pakastekuivattuja pallosia
ES2063173T3 (es) Empleo de polietileniminas alquiladas como medicamentos absorbedores de acido biliar, asi como preparados farmaceuticos.
NO20005431D0 (no) Gelérbare farmasøytiske preparater
ES2058411T3 (es) Sustancia fr 901228 y su preparacion.
BR9206632A (pt) Sistema de penetração na pele melhorado para melhorada liberação tópica de drogas
BR9908273A (pt) Formulações
DK0971705T3 (da) Lægemiddelformuleringer til hormonerstatningsterapi til lokal påföring på huden
IS1565B (is) Aðferð við framleiðslu á N1-súbstitúeruðum bensimidasólafleiðum til að nota við lækningar
SE8504945L (sv) Farmaceutiska kompositioner innehallande antracyklinglykosider
MY111841A (en) Injectable liposomal pharmaceutical preparations
FI886019A7 (fi) Laastari vaikuttavien aineiden valvotusti jakamiseksi iholle
EP0009688A3 (en) Medicated animal food based on liver powder, process for its preparation and its use in combating animal diseases
FI954497L (fi) Aktiivista ainetta sisältävä laastari estradiolin vapauttamiseksi ihoon
EP0682942A4 (en) NEW ABSORBABLE PERCUTANEOUS PREPARATION.
DK0482097T3 (da) Tensidpræparater og fremgangsmåder
ES2016620B3 (es) Sistema para liberar medicamentos con bioaceptabilidad mejorada.
ES2077559T3 (es) Estabilizacion de proteinas terapeuticamente activas en preparados farmaceuticos.
NO306762B1 (no) Anvendelse av lanolinderivater sammen med polyetylenglykoletere, blanding derav og transdermalt terapeutisk system
ES2158094T3 (es) Sales de adicion de acido de compuestos de 2,3,4,5-tetrahidro-1h-3-benzazepina.
AU6415994A (en) Substituted caprolactams and derivatives thereof useful for treatment of hiv disease
DK0719276T3 (da) Ïstradiolestre med stærk oral virkning samt farmaceutiske præparater med indhold deraf
FI853228A7 (fi) Uudet -butyrolaktaamit, niiden farmaseuttisesti aktiiviset koostumukset, menetelmät niiden valmistamiseksi ja niiden käyttö lääkeaineina.
EP0227531A3 (en) Pyroglutamic acid esters used as dermal penetration enhancers for drugs

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 710103

Country of ref document: ES